LockBody® Technology Platform
Aiming to redefine immuno-oncology treatment for patients with cancer
Our team of scientists at Centessa are continuously inspired by both professional and personal experiences surrounding the unmet needs in cancer therapy, particularly the gap in cancer treatments that are both efficacious and safe. Our proprietary LockBody® technology platform hopes to tackle these unmet needs.
LockBody® antibodies are designed to selectively drive potent effector function activity to the tumor microenvironment while avoiding systemic toxicity.
Novel MOA
LOCKED CONFIGURATION
outside the tumor microenvironment
Constitutive Fabs – For targets expressed in diseased tissues; drive tumor enrichment
Locked Contingent Fabs – For potent immune efectors (e.g. CD3); remain blocked by constitutive fabs.
Fc Region
IgG1-derived Hinges – Naturally resistant to cleavage in serum
UNLOCKED CONFIGURATION
inside the tumor microenvironment
Unlocked Contingent Fabs – Activate effector function activity in the tumor microenvironment (e.g., CD3)
Exposed CDRs
IgG1-derived Hinges – Susceptible to cleavage in diseased tissue by various natural processes
Our LockBody® antibodies are designed to:
Avoid the ‘sink effect’
Stability of the LockBody® in the periphery minimizes unwanted binding to effector targets highly expressed in the blood and secondary lymphoid tissue. This design has the potential to lower effective doses and mitigate the risk of toxicity.
Enable a potentially dramatic enhanced therapeutic index
To fully activate LockBody®, two criteria are needed: the presence of an appropriate binding target of the constitutively-active upper Fabs and a highly proteolytic environment enriched with effector function. This dual requirement may potentially widen the therapeutic index and provide access to potent effector mechanisms.
Support high manufacturing yields and low immunogenicity
As all the components of a LockBody® are based on native, human IgG structures they have the potential to retain all the key benefits of standard therapeutic antibodies including high manufacturing yields and low immunogenicity.
